<code id='CB02E7334C'></code><style id='CB02E7334C'></style>
    • <acronym id='CB02E7334C'></acronym>
      <center id='CB02E7334C'><center id='CB02E7334C'><tfoot id='CB02E7334C'></tfoot></center><abbr id='CB02E7334C'><dir id='CB02E7334C'><tfoot id='CB02E7334C'></tfoot><noframes id='CB02E7334C'>

    • <optgroup id='CB02E7334C'><strike id='CB02E7334C'><sup id='CB02E7334C'></sup></strike><code id='CB02E7334C'></code></optgroup>
        1. <b id='CB02E7334C'><label id='CB02E7334C'><select id='CB02E7334C'><dt id='CB02E7334C'><span id='CB02E7334C'></span></dt></select></label></b><u id='CB02E7334C'></u>
          <i id='CB02E7334C'><strike id='CB02E7334C'><tt id='CB02E7334C'><pre id='CB02E7334C'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:278

          This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

          I have one more, admittedly braggy thing to say about last week’s STAT Breakthrough Summit West in San Francisco. Of course we curated an incredible roster of influential industry leaders to speak on stage. That’s what STAT does. But just as remarkable were the health care and health tech A-Listers who just showed up as summit attendees to listen and learn from their peers — like 23AndMe’s Anne Wojcicki. Please join us in San Francisco next year, or better yet, register for our next summit in Boston, Oct. 16-17.

          advertisement

          I’m back in Boston from San Francisco, but flying out again next week, this time to Chicago for the annual meeting of the American Society of Clinical Oncology. How can we be knocking on June, already?

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Appeals court upholds limits to abortion pill
          Appeals court upholds limits to abortion pill

          AfederalappealscourtonWednesdayruledtorestrictaccesstotheabortionpillmifepristonebutnotremoveitfromt

          read more
          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more

          AstraZeneca challenges Medicare drug negotiation program

          AstraZenecaissuingtheBidenadministrationtostopanewMedicaredrugpricenegotiationprogram.AdobeWASHINGTO